A Population-Based Cohort Study analyzing whether nirmatrelvir plus ritonavir reduces risk for hospitalization or death among outpatients with early COVID-19
Latest Information Update: 16 Dec 2022
At a glance
- Drugs Nirmatrelvir+ritonavir (Primary)
- Indications COVID 2019 infections
- Focus Therapeutic Use
Most Recent Events
- 16 Dec 2022 New trial record
- 13 Dec 2022 Results published in the Annals of Internal Medicine